Alamar Biosciences, Inc. (ALMR) · Nov 3, 2026 · Earnings
Beat — Revenue $33.5M vs ~$30.2M consensus; EPS $(0.19) vs ~$0.20 loss consensus
Alamar’s third-quarter earnings beat expectations and lifted 2026 revenue guidance, reinforcing demand for its proteomics platform despite heavier operating losses.
Alamar is a commercial-stage precision-proteomics company scaling its NULISA assays and ARGO instruments across research institutions and biopharma, with consumables and new instrument placements driving the growth engine. Its prior quarter already showed accelerating demand and full-year 2026 revenue guidance of $116 million to $120 million, so the direction was known; this filing raises the magnitude of the outlook.
The quarter was a clear top-line beat. Revenue reached $33.5 million, ahead of published expectations around $30.2 million, while consumables grew faster than instruments and services—evidence that the installed-base model is beginning to generate repeat usage, not just one-time instrument sales. The filing says, “Revenue was $33.5million for the third quarter of 2026, a 68% increase from $19.9million for the corresponding prior-year period.”
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Revenue (Financial Results) | $33.5M (+68%) | $19.9M | ~$30.2M |
| Gross margin (Financial Results) | 61.5% | 59.7% | |
| Operating loss (Financial Results) | $15.1M | $7.9M | |
| Net loss (Financial Results) | $13.3M | $8.0M | |
| Diluted EPS (Income Statement) | $(0.19) | $(0.69) | ~$(0.20) |
| FY 2026 revenue guidance (2026 Guidance) | $121M–$123M | $116M–$120M prior guide |
The guidance raise is the most important change to the business story. Alamar lifted its 2026 revenue range to $121 million–$123 million from $116 million–$120 million, implying the company is converting current demand into a higher expected full-year run rate rather than merely benefiting from a single strong quarter. The filing states, “Alamar Biosciences now expects full year 2026 revenue to be in the range of $121 to $123million.”
The counterweight is that Alamar is buying growth with much heavier spending. Operating expenses rose 81%, pushing the operating loss to $15.1 million from $7.9 million, while stock-based compensation increased to $3.9 million from $0.7 million. The revenue acceleration is therefore real, but the filing does not show operating leverage yet; it shows a company still investing aggressively in headcount, infrastructure, R&D and public-company costs.
The president’s planned retirement adds transition risk but not an immediate disruption. Tod White leaves the presidency on December 31, 2026 after helping scale operations, fundraising and the IPO, but remains an advisor through June 30, 2027. Because the handoff is announced in advance and includes a six-month consulting period, it complicates execution modestly rather than changing the core growth thesis. The filing says, “Mr. White has agreed to remain as a consultant to the Company from January 1, 2027 through June 30, 2027 to ensure an orderly transition and continuity of operations.” 〔0〕
Bottom line: This was a meaningful upside update to Alamar’s growth story: revenue beat expectations and the company raised its full-year target. The main limitation is that profitability remains distant as spending and dilution-related compensation rise, but that does not outweigh the stronger-than-expected commercial traction in this filing.
Tod White retires December 31; advisor through June 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!